Wed, 26 Jun 2024 | BUSINESS SALE
Nottingham-based chromatography provider Reach Separations has been acquired by Cardiff-headquartered CatSci in a deal supported by private equity manager Keensight Capital. The deal is described as a significant milestone for CatSci, an innovation partner for medicines development, as it continues to enhance its CMC (Chemistry, Manufacturing and Controls) offering.
Reach Separations, which has laboratories in the UK and France, specialises in providing chromatography for the analysis and purification of chiral and achiral therapeutics. The acquisition is effective immediately and will enable CatSci to provide global customers with access to holistic chromatographic services that can be used throughout their processes, from discovery to manufacture.
CatSci Chief Executive Dr Ross Burn commented: “The need for solving complex analytical problems while meeting the ever-evolving regulatory demands is growing alongside the development of new modalities, such as oligonucleotides, TACs (Targeting Chimeras), and glues.”
"Joining forces with Reach gives our customers access to end-to-end coverage of the analytical development lifecycle, taking them from discovery through to GMP manufacture, and ultimately enabling them to help patients in need.’"
Reach Separations Business Development Director Peter Ridgway said that joining the CatSci group would “enhance and strengthen [the company’s] ability to deliver excellence in chromatography.”
He continued: “Integrating our technologies and expertise across the discovery and development landscape will provide a one-stop-shop for analysis and purification, giving the client a variety of options to progress the journey of their asset.”
Keensight Capital partner James Mitchell said that the firm would continue to support CatSci Group during their next phase of growth.
Mitchell added: "Having identified CatSci as a company with exceptional potential, unique positioning and strong expertise in the small molecule R&D, we believe that the addition of Reach’s differentiated offering, analytical capabilities and strong employee base will ensure that the combined company is well positioned for future growth in this space."
Discover how companies can attract private equity backing for their acquisitive growth plans
Established 2019, this well-established, domiciliary care facility located in Chesterfield is offered for sale.
RELOCATABLE
Represents an opportunity for an acquirer seeking a private dentistry based in Cheshire, and boasting 3 well-equipped, modern surgeries.
FREEHOLD
This is a denovo dentistry opportunity including land and planning permission granted. Principal is happy to stay-on and accept an earn-out, demonstrating the safety of your investment.
FREEHOLD
Please choose your settings for this site below. For more information please read our Cookie Policy
These cookies are necessary for our website to function properly and provide you with access to all features.
These are analytics cookies that help us to improve the way our website works.
These are used to improve the functional performance of the website and make it easier for you to use.